Millions of individuals worldwide suffer from acute and, more severely, chronic pain conditions (e.g., neuropathic pain, and migraine). The latter bear tremendous personal, familial, and social costs, since sufferers and their relatives undergo a complete turnaround of their lives with the search of relief from pain becoming their pivotal thought. Sadly, to date no effective pharmacological approaches are available which can alleviate chronic pain significantly or in the long run in all patients. The current central strategy for the development of new and effective painkillers lies in the hypothesis that cellular and/or molecular players in nociception must exists that are not targeted by "classical" analgesics, and therefore researchers have put tremendous efforts into the in-depth analysis of the pathways leading to pain development and maintenance over time. In this complex scenario, two outsiders are now taking the center stage: glial cells in sensory ganglia and in the central nervous system, thanks to their ability to communicate with neurons and to modulate their firing, and the purinergic system. Extracellular purine and pyrimidine nucleotides are involved in the physiology of virtually every body district, and their extracellular concentrations massively increase under pathological situations, suggesting that they might represent potential targets for the modulation of disease-associated symptoms, like pain. Here, we provide an overview of the present knowledge of the role of nucleotides in nociception, with a particular emphasis on G protein-coupled P2Y receptors and their involvement in the communication between first- and second-order neurons in sensory nerve pathways and surrounding glial cells.

P2Y purinergic receptors: new targets for analgesic and antimigraine drugs / G. Magni, S.M. Ceruti. - In: BIOCHEMICAL PHARMACOLOGY. - ISSN 0006-2952. - 85:4(2013 Feb 15), pp. 466-477. [10.1016/j.bcp.2012.10.027]

P2Y purinergic receptors: new targets for analgesic and antimigraine drugs

G. Magni
Primo
;
S.M. Ceruti
2013

Abstract

Millions of individuals worldwide suffer from acute and, more severely, chronic pain conditions (e.g., neuropathic pain, and migraine). The latter bear tremendous personal, familial, and social costs, since sufferers and their relatives undergo a complete turnaround of their lives with the search of relief from pain becoming their pivotal thought. Sadly, to date no effective pharmacological approaches are available which can alleviate chronic pain significantly or in the long run in all patients. The current central strategy for the development of new and effective painkillers lies in the hypothesis that cellular and/or molecular players in nociception must exists that are not targeted by "classical" analgesics, and therefore researchers have put tremendous efforts into the in-depth analysis of the pathways leading to pain development and maintenance over time. In this complex scenario, two outsiders are now taking the center stage: glial cells in sensory ganglia and in the central nervous system, thanks to their ability to communicate with neurons and to modulate their firing, and the purinergic system. Extracellular purine and pyrimidine nucleotides are involved in the physiology of virtually every body district, and their extracellular concentrations massively increase under pathological situations, suggesting that they might represent potential targets for the modulation of disease-associated symptoms, like pain. Here, we provide an overview of the present knowledge of the role of nucleotides in nociception, with a particular emphasis on G protein-coupled P2Y receptors and their involvement in the communication between first- and second-order neurons in sensory nerve pathways and surrounding glial cells.
Nucleotides; P2 receptors; Satellite glial cells; Microglia; Migraine; Algogens
Settore BIO/14 - Farmacologia
15-feb-2013
9-nov-2012
Article (author)
File in questo prodotto:
File Dimensione Formato  
Magni_Ceruti_REVISED_FINAL.pdf

accesso aperto

Descrizione: Articolo con figure e tabelle
Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 2.09 MB
Formato Adobe PDF
2.09 MB Adobe PDF Visualizza/Apri
1-s2.0-S0006295212007265-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 733.48 kB
Formato Adobe PDF
733.48 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/220479
Citazioni
  • ???jsp.display-item.citation.pmc??? 22
  • Scopus 56
  • ???jsp.display-item.citation.isi??? 49
social impact